In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Immuno-Oncology Is Making Pharma Step Up Its Diagnostics Game

Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.

ImmunoOncology Diagnostics Cancer

Value-Based Health Care: US Lags In The Global Shift To Outcomes

The adoption of value-based health care concepts among US providers is happening, albeit slowly. In what is an unusual reversal of pioneering health care concepts, the pace is being set elsewhere – in Europe – rather than in the US, even if the direction of travel has been firmly established. Boston Consulting Group experts give In Vivo an interim update on the progress and outlook for VBHC.

Market Access Medical Device Business Strategies

Growing Pipelines, Promising Candidates Bring Gene Therapy To The Next Level

Advances in gene therapy have created a dynamic pipeline. A recent Datamonitor Healthcare report examines various trends in that pipeline, including vector types used, in vivo versus ex vivo approaches, and therapy areas being targeted.

Regenerative Medicine Market Intelligence

In Vivo's Deals Of The Month, January 2018

In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)

Deals Market Intelligence BioPharmaceutical
Advertisement

2018 Outlook

Insights from In Vivo on what to expect in the coming year


Recent Tweets from In Vivo


Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio

Mid-size biopharma companies are industry’s “stealth” players, occupying a small but important space in the race for new innovative therapies. In Vivo explores the growth prospects of one of the more prominent entrants in this space, Merck KGAA, whose fortunes depend heavily on building a strong oncology and immunology franchise in the US market.

BioPharmaceutical Growth

Biopharma R&D Productivity And Growth 2017: Big Pharma Closes The Gap

Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

BioPharmaceutical Research and Development Strategies

True To Its Word, LivaNova Sheds CRM – To MicroPort

One of the cleanest and swiftest M&A deals of recent months was the twinning of LivaNova's CRM business with MicroPort's enhanced ambitions in a $10 billion global market. What now for these two medtech innovators?

Business Strategies M & A

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas

Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.

Clinical Trials ImmunoOncology

Thirty-five Years Covering Health Care: The More Things Change…

The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.

BioPharmaceutical Medical Device

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, February 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Deals Driving Oncology: ImmunoGen CEO Mark Enyedy on Biopharma’s Year Ahead

Cancer continues to reign in 2018 as the emperor of all maladies, with almost boundless opportunities for companies with a solid base in new science and a differentiated therapy set that can be tailored to the needs of individual patients not served by the current standard of care. ImmunoGen CEO Mark Enyedy tells In Vivo that there’s never been a better time for drugmakers in the oncology marketplace.

Deals Leadership

Execs On The Move, January 2018

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?

2018 will be a time of transition in health care, when biopharma’s counterparts in adjacent industry segments scale up in a radical redesign of their traditional business models. Biopharma is not moving as quickly, and it confronts a strategic dilemma on how to address the prospect of a much more powerful set of rivals in the ongoing battle to own the patient experience in medicine.

BioPharmaceutical Business Strategies

Medtech 2018: The Place For Innovation As Value-based Health Care Gains Momentum

2017 was a watershed year in many respects, politically, economically and commercially for many players in the medtech field. Where will the opportunities lie in 2018, will breakthrough medtech innovation still have a place among providers often riding on fumes when it comes to budgets, and is it all as bad as some would make out?

International Medical Device

Resilience Is Key For Medtechs Facing Provider And Payer Flux In 2018

Medtech firms entered 2018 knowing that demands from providers and payers are increasing, the pace of business is quickening, and at the same time patients are more empowered and market access routes are more exacting than ever. Against this backdrop, PwC explains the top health industry issues for the coming year, highlights the forces that will have the most impact on the industry in 2018 and explains why manufacturers need to be nimble.

Medical Device Business Strategies

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device

Deals In Depth: December 2017

In a billion-dollar alliance, Roivant Sciences got exclusive rights to HanAll's neonatal Fc receptor-targeting antibody for autoimmune diseases. CVS is hoping to improve health care delivery and costs with the $77 billion acquisition of insurer Aetna. Financing in both the biopharma and devices industries was down from last month.

Deals Market Intelligence

No Seismic Shifts As Torrential Rain Dampens JPM Jamboree

Drug pricing, diversity and US tax reform dominated discussions at JP Morgan. Deals announced at the conference didn't spark much excitement, but attendees were confident that the biopharma sector will still get capital market support.

BioPharmaceutical Business Strategies
UsernamePublicRestriction

Register

Advertisement